Fig. 5
L1-FGGY exhibited an oncogenic role dependent on activation of 12-LOX/GPR31 metabolic pathway. A The relative RNA expression values of 5-LOX, 12-LOX and 15-LOX detected in 147 LUSC tumor samples (77 L1-FGGY+ vs. 70 L1-FGGY−) from TJMUCH. B The OS was compared between 5-LOX+ and 5-LOX−, 12-LOX+ and 12-LOX−, 15-LOX+ and 15-LOX− patients respectively grouped according to mRNA levels. C Different resolutions of IHC staining results of the FGGY, 12-LOX, 15-LOX and GPR31 antigen expression in L1-FGGY− and L1-FGGY+ LUSC tumor samples. The statistical results of IHC staining were shown at right. D The relative RNA expression of 12-LOX and 15-LOX detected in H520OV−CTRL and H520OV−L1−FGGY, as well as in H520OV−L1−FGGY treated with either ML355 or PD146176. E The secretion value of 12S-HETE and 15S-HETE detected in H520OV−CTRL, H520OV−L1−FGGY, and H520OV−L1−FGGY treated with either ML355 or PD146176. F The proliferation of H520OV−CTRL, H520OV−L1−FGGY, H520OV−L1−FGGY+sh−GPR31, and H520OV−L1−FGGY treated with either ML355 or PD146176 was detected using CCK8 method. G Representative images of H520OV−CTRL, H520OV−L1−FGGY, H520OV−L1−FGGY+sh−GPR31, and H520OV−L1−FGGY treated with either ML355 or PD146176 in wound healing assays. The statistical results of migration rate were shown at the right of the panel. (H) Representative images of H520OV−CTRL, H520OV−L1−FGGY, H520OV−L1−FGGY+sh−GPR31, and H520OV−L1−FGGY treated with either ML355 or PD146176 in trans-well invasion assays. The statistical results of invasion number were shown at right. The data are shown as mean ± SD with plots. * and ** indicate p < 0.05 and p < 0.01, respectively between the groups as indicated